To verify whether trametinib plus CuET affects the survival of BRAF WT melanoma cells in a more physiological three-dimensional (3D) environment, we evaluated the cellular viability of melanoma spheroids in a short-term viability assay. The gene discussed is BRAF; the disease is melanoma.